...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
【24h】

Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.

机译:phoPQ和pmrAB两组分调节系统的改变与铜绿假单胞菌临床分离株中的多粘菌素B耐药有关。

获取原文
获取原文并翻译 | 示例
           

摘要

Polymyxins are often the only option to treat acquired multidrug-resistant Pseudomonas aeruginosa. Polymyxin susceptibility in P. aeruginosa PAO1 is associated with the lipopolysaccharide structure that is determined by arnBCADTEF and modulated by phoPQ and pmrAB. We examined five clonally unrelated clinical isolates of polymyxin B-resistant P. aeruginosa to investigate the molecular basis of polymyxin resistance. All isolates grew with 4 microg/ml polymyxin B (MIC, 8 microg/ml), whereas P. aeruginosa PAO1 grew with 0.25 mug/ml polymyxin B (MIC, 0.5 microg/ml). The resistant isolates were converted to susceptible ones (the MICs fell from 8 to 0.5 microg/ml) following the introduction of phoPQ (four isolates) and pmrAB (one isolate), which had been cloned from strain PAO1. DNA sequence analysis revealed that a single-nucleotide substitution in three isolates replaced a single amino acid of PhoQ, the deletion of 17 nucleotides in one isolate truncated the protein of PhoQ, and two nucleotide substitutions in one isolate replaced two amino acids of PmrB. The involvement of these amino acid substitutions or the truncated protein of PhoQ and PmrB in polymyxin B resistance was confirmed using strain PAO1 lacking phoPQ or pmrAB that was transformed by phoPQ or pmrAB containing the amino acid substitutions or the truncated protein. The resistant clinical isolates were sensitized by the inactivation of arnBCADTEF (the MICs fell from 8 to 0.5 microg/ml). These results suggest that polymyxin B resistance among clinical isolates of P. aeruginosa is associated with alterations in two-component regulatory systems of phoPQ or pmrAB.
机译:多粘菌素通常是治疗获得性多药耐药的铜绿假单胞菌的唯一选择。铜绿假单胞菌PAO1中的多粘菌素敏感性与脂蛋白结构有关,脂蛋白结构由arnBCADTEF确定,并由phoPQ和pmrAB调节。我们检查了五个多克隆毒素抗性铜绿假单胞菌的无性系无关临床分离株,以研究多粘菌耐药性的分子基础。所有分离株均以4微克/毫升多粘菌素B(MIC,8微克/毫升)生长,而铜绿假单胞菌PAO1则以0.25杯/毫升多粘菌素B(MIC,0.5微克/毫升)生长。在引入从菌株PAO1克隆的phoPQ(四种分离株)和pmrAB(一种分离株)后,抗性分离株转化为易感分离株(MIC从8降至0.5微克/毫升)。 DNA序列分析显示,三个分离株中的一个单核苷酸替代物替换了PhoQ的一个氨基酸,一个分离物中17个核苷酸的缺失截短了PhoQ的蛋白,一个分离物中的两个核苷酸替代物替换了PmrB的两个氨基酸。使用缺少phoPQ或pmrAB的PAO1菌株(由含有氨基酸取代或截短的phoPQ或pmrAB转化的PAO1菌株)证实了这些氨基酸取代或PhoQ和PmrB的截短蛋白参与了多粘菌素B抗性。 arnBCADTEF的失活使抗药性临床分离株致敏(MIC从8降至0.5微克/毫升)。这些结果表明,铜绿假单胞菌临床分离株中的多粘菌素B耐药性与phoPQ或pmrAB的两组分调节系统的改变有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号